We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App





Cepheid Unveils Third-Generation GeneXpert System at ADLM 2026

By LabMedica International staff writers
Posted on 27 Jul 2026

Cepheid  is unveiling the third generation of its GeneXpert molecular diagnostic system at the Association for Diagnostics & Laboratory Medicine (ADLM) 2026 Annual Scientific Meeting. More...

The company is presenting the new platform during a special event on Tuesday, July 28, highlighting its expanded capabilities for PCR-based testing.

The third-generation GeneXpert system is designed to broaden the range of molecular testing available on a single platform while retaining the simplicity, flexibility, and reliability of existing GeneXpert workflows. According to the company, the system supports laboratories seeking to consolidate different types of molecular testing that may otherwise require multiple instruments and processes.

At launch, the platform is designed to support Cepheid’s comprehensive menu of U.S. Food and Drug Administration-cleared Xpert tests. It introduces a fully integrated touchscreen interface, redesigned software, and a more intuitive user experience while maintaining the workflows currently used by GeneXpert customers.

The system is also being developed to support a new generation of Xpert tests and applications. Planned capabilities include high-plex panel testing, faster time to results, and additional sample-to-answer solutions that could extend to next-generation sequencing workflows.

Like the company’s existing GeneXpert systems, the new platform provides random-access testing, allowing laboratories to process samples as they arrive rather than waiting to assemble batches. This approach enables urgent samples to be prioritized while supporting rapid access to actionable results across different healthcare environments.

The first configuration scheduled for release is a compact four-module system, with shipments to U.S. customers expected to begin in the coming months. Cepheid is also developing higher-capacity GeneXpert configurations and new GeneXpert Infinity systems for laboratories with larger testing volumes. The systems remain in development and have not been reviewed by a regulatory authority for diagnostic use.

Cepheid’s unveiling forms part of Danaher’s broader presence at ADLM 2026. At booth 3237, visitors can explore technologies from Danaher operating companies including Beckman Coulter Diagnostics, Beckman Coulter Life Sciences, Cytiva, HemoCue, Leica Biosystems, Radiometer, and SCIEX, covering diagnostic and life sciences workflows from discovery through clinical delivery.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Hematology Consumables
Bioblood Devices
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.